Generic Brovana Availability

Brovana is a brand name of arformoterol, approved by the FDA in the following formulation(s):

BROVANA (arformoterol tartrate - solution;inhalation)

  • Manufacturer: SUNOVION
    Approval date: October 6, 2006
    Strength(s): EQ 0.015MG BASE/2ML [RLD]

Has a generic version of Brovana been approved?

No. There is currently no therapeutically equivalent version of Brovana available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brovana. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Formoterol process
    Patent 6,040,344
    Issued: March 21, 2000
    Inventor(s): Gao; Yun & Hett; Robert & Fang; Kevin Q. & Wald; Stephen A. & Redmon; Martin P. & Senanayake; Chris Hugh
    Assignee(s): Sepracor Inc.
    A method is disclosed for the preparation of optically pure isomers of formoterol by the reaction of an optically pure 4-benzyloxy-3-formamidostyrene oxide with an optically pure 4-methoxy-.alpha.-methyl-N-(phenylmethyl)benzeneethanamine followed by debenzylation. Useful intermediates in the process are also disclosed, as are the novel L-tartrate salt of R,R-formoterol and pharmaceutical compositions thereof.
    Patent expiration dates:
    • November 12, 2016
      ✓ 
      Drug substance
  • Formoterol tartrate process and polymorph
    Patent 6,472,563
    Issued: October 29, 2002
    Inventor(s): Gerald J.; Tanoury & Chris H.; Senanayake & Donald W; Kessler
    Assignee(s): Sepracor Inc.
    A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
    Patent expiration dates:
    • November 9, 2021
      ✓ 
      Drug substance
  • Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol
    Patent 6,589,508
    Issued: July 8, 2003
    Inventor(s): Gunnar; Aberg & John; Morley
    Assignee(s): Sepracor Inc.
    A method and composition are disclosed utilizing the pure (R,R) isomer of formoterol, which is a potent bronchodilator with reduced adverse effects, having a low incidence of the development of tolerance and having increased duration of action.
    Patent expiration dates:
    • April 3, 2014
      ✓ 
      Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  • Bronchodilating compositions and methods
    Patent 6,667,344
    Issued: December 23, 2003
    Inventor(s): Partha S.; Banerjee & Stephen; Pham & Samuel O.; Akapo & Imtiaz A.; Chaudry
    Assignee(s): Dey, L.P.
    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Patent expiration dates:
    • June 22, 2021
      ✓ 
      Drug product
  • Formoterol tartrate polymorph
    Patent 6,720,453
    Issued: April 13, 2004
    Inventor(s): Gerald J.; Tanoury & Chris H.; Senanayake & Donald W; Kessler
    Assignee(s): Sepracor Inc.
    A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
    Patent expiration dates:
    • November 9, 2021
      ✓ 
      Drug substance
  • Bronchodilating compositions and methods
    Patent 6,814,953
    Issued: November 9, 2004
    Inventor(s): Partha S.; Banerjee & Stephen; Pham & Samuel O.; Akapo & Imtiaz A.; Chaudry
    Assignee(s): Dey L.P.
    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Patent expiration dates:
    • June 22, 2021
      ✓ 
      Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  • Formoterol tartrate polymorph
    Patent 7,145,036
    Issued: December 5, 2006
    Inventor(s): Tanoury; Gerald J. & Senanayake; Chris H. & Kessler; Donald W.
    Assignee(s): Sepracor Inc.
    A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
    Patent expiration dates:
    • November 9, 2021
      ✓ 
      Drug substance
  • Bronchodilating β-agonist compositions and methods
    Patent 7,348,362
    Issued: March 25, 2008
    Inventor(s): Banerjee; Partha S. & Chaudry; Imtiaz A. & Pham; Stephen
    Assignee(s): Dey, L.P.
    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Patent expiration dates:
    • June 22, 2021
      ✓ 
      Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
      ✓ 
      Drug product
  • Bronchodilating beta-agonist compositions and methods
    Patent 7,462,645
    Issued: December 9, 2008
    Inventor(s): Chaudry; Imtiaz A. & Pham; Stephen & Banerjee; Partha S.
    Assignee(s): JPMorgan Chase Bank, N.A.
    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Patent expiration dates:
    • June 22, 2021
      ✓ 
      Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  • Bronchodilating beta-agonist compositions and methods
    Patent 7,465,756
    Issued: December 16, 2008
    Inventor(s): Chaudry; Imtiaz A. & Pham; Stephen & Banerjee; Partha S.
    Assignee(s): JPMorgan Chase Bank, N.A.
    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Patent expiration dates:
    • June 22, 2021
      ✓ 
      Drug product
  • Bronchodilating beta-agonist compositions and methods
    Patent 7,473,710
    Issued: January 6, 2009
    Inventor(s): Chaudry; Imtiaz A. & Pham; Stephen & Banerjee; Partha S.
    Assignee(s): JPMorgan Chase Bank, N.A.
    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Patent expiration dates:
    • June 22, 2021
      ✓ 
      Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  • Bronchodilating β-agonist compositions and methods
    Patent 7,541,385
    Issued: June 2, 2009
    Inventor(s): Chaudry; Imtiaz A. & Pham; Stephen & Banerjee; Partha S.
    Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.
    Patent expiration dates:
    • June 22, 2021
      ✓ 
      Patent use: FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
  • Formoterol tartrate process and polymorph
    Patent 8,110,706
    Issued: February 7, 2012
    Inventor(s): Tanoury; Gerald J. & Senanayake; Chris H. & Kessler; Donald W.
    Assignee(s): Sunovion Pharmaceuticals Inc.
    A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
    Patent expiration dates:
    • November 9, 2021
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)